Drug intelligence / Profile preview

TP-164

Development stage: Unknown
Lead developer: TechnoPhage
Modality: Live Biotherapeutic Products → Microbiome Therapeutics

Overview

TP-164 is a bacteriophage therapy developed by TechnoPhage for the treatment of infectious diseases, specifically targeting urinary tract infections. As a bacteriophage-based product, its mechanism involves the use of viruses (bacteriophages) that infect and lyse specific bacterial pathogens responsible for urinary tract infections. The drug is currently in the discovery phase and has not yet entered clinical trials or received regulatory approval[1][2][6].

Beyond the preview

Go deeper on TP-164.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TP-164.

Explore the full profile